ArticleOncoimmunology2023

A PD-L1/EGFR bispecific antibody combines immune checkpoint blockade and direct anti-cancer action for an enhanced anti-tumor response.

Laura Rubio-Pérez et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.